[News Article] Samsung Biologics lands further Pfizer deals in record year
Samsung Biologics
lands further Pfizer deals in record year
BY SHIN HA-NEE, Korea
JoongAng Daily - Pharma manufacturer Samsung Biologics has secured $897 million
worth of deals from Pfizer Ireland Pharmaceuticals, the Incheon-based company
said Tuesday. The deals, which
followed a letter of intent signed with Pfizer in June, are a $704-million
contract manufacturing organization (CMO) deal and an additional $193 million
order from a previous contract worth $183 million inked on March 2. CMOs refer to
companies that provide drug manufacturing services on a contract basis. With the addition of
the latest contracts, Samsung Biologics’ contract value this year from Pfizer
totals $1.08 billion. The combined value
of all of the CMO contracts signed by Samsung Biologics so far this year comes
in at $1.49 billion, already outrunning last year’s total of $1.37 billion. The contracts marked
the largest CMO deals ever for Samsung Biologics since the company’s
establishment in 2011, surpassing a $351 million deal with AstraZeneca in 2020. The two contracts
are a follow-up of the $411-million letter of intent announced in a regulatory
filing on June 8. Under the deals, Samsung Biologics will manufacture Pfizer's
biosimilar products including tumor and inflammation treatments at its fourth
plant in Songdo. Samsung Biologics
recently started full operation of its fourth plant, in Songdo, Incheon, which
has a production capacity of 240,000 liters (63,401 gallons). It is the world’s
largest single pharmaceutical manufacturing facility. The latest plant
brought the company's annual production capacity to 604,000 liters, which
Samsung Biologics said is equivalent to nearly 30 percent of the global
contract manufacturing market for biopharmaceuticals. Moreover, Samsung
Biologics announced in March that it will invest 1.98 trillion won ($1.5
billion) to build its fifth production plant, which started construction in
April. While Samsung
Biologics previously stated in a regulatory filing that the commercial
operation of Plant 5 will begin on September 2025, the project is expected to
be fast-tracked by five months. The upcoming Plant 5
will sit on a 96,000 square-meter (23-acre) site in Bio Campus II, Samsung
Biologics’ new manufacturing complex in Songdo. Once the new
factory, which will have a 180,000-liter production capacity, begins
operations, Samsung Biologics said it will boast the largest combined
production capacity among global biomedicine contract manufacturers at 784,000
liters. The company is
currently operating a research and development center for contract development
in San Francisco, which was established in 2020, and opened a local sales
office in New Jersey in March. Samsung Biologics'
share price closed at 746,000 won on Tuesday, up 0.4 percent from the previous
trading day. Source: https://koreajoongangdaily.joins.com/2023/07/04/business/industry/Korea-Samsung-Biologics-CDMO/20230704150421743.html
2023.07.07